Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
Volume: 36, Issue: 8, Pages: 2180 - 2186
Published: Mar 31, 2021
Abstract
E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation. We evaluated the safety and pharmacokinetic profile of E6011 in patients with Crohn's disease (CD) and also performed preliminary pharmacodynamic (PD) and efficacy assessments.This study included a 12-week multiple ascending dose (MAD) phase (2, 5, 10, and 15 mg/kg intravenously every 2 weeks, n = 6,...
Paper Details
Title
Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
Published Date
Mar 31, 2021
Volume
36
Issue
8
Pages
2180 - 2186
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History